82 related articles for article (PubMed ID: 34429056)
1. Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study.
Reuter U; Goadsby PJ; Ferrari MD; Da Silva Lima GP; Mondal S; Kalim J; Hasan F; Wen S; Arkuszewski M; Pandhi S; Stites T; Lanteri-Minet M
Neurology; 2024 May; 102(10):e209349. PubMed ID: 38669638
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis.
Fernández-Bravo-Rodrigo J; Cavero-Redondo I; Lucerón-Lucas-Torres M; Martínez-García I; Flor-García A; Barreda-Hernández D; Pascual-Morena C
Eur J Pharmacol; 2024 Aug; 976():176702. PubMed ID: 38823758
[TBL] [Abstract][Full Text] [Related]
3. Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial.
Pozo-Rosich P; Dolezil D; Paemeleire K; Stepien A; Stude P; Snellman J; Arkuszewski M; Stites T; Ritter S; Lopez Lopez C; Maca J; Ferraris M; Gil-Gouveia R
JAMA Neurol; 2024 May; 81(5):461-470. PubMed ID: 38526461
[TBL] [Abstract][Full Text] [Related]
4. Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study.
Tepper SJ; Fang J; Vo P; Shen Y; Zhou L; Abdrabboh A; Glassberg M; Ferraris M
J Headache Pain; 2021 Apr; 22(1):27. PubMed ID: 33874884
[TBL] [Abstract][Full Text] [Related]
5. Migraine day frequency in migraine prevention: longitudinal modelling approaches.
Di Tanna GL; Porter JK; Lipton RB; Brennan A; Palmer S; Hatswell AJ; Sapra S; Villa G
BMC Med Res Methodol; 2019 Jan; 19(1):20. PubMed ID: 30674285
[TBL] [Abstract][Full Text] [Related]
6. Real-world treatment satisfaction with erenumab in migraine: analysis of the US National Health and Wellness Survey.
Pathak P; Yue L; Gupta S; Fang J; Cheadle MA; Tiwari S; Ferraris M; Joshi P; Thompson J; Shah R; Vo P
Curr Med Res Opin; 2023 Dec; 39(12):1585-1591. PubMed ID: 36919462
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open-label, multiple-dose study.
Hershey AD; Paiva da Silva Lima G; Pannacciulli N; Mackowski M; Koukakis R; McVige JW
Clin Transl Sci; 2024 Mar; 17(3):e13755. PubMed ID: 38476099
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the effect of erenumab on migraine-specific questionnaire in patients with chronic and episodic migraine.
Chen PW; Karlsson MO; Ueckert S; Pritchard-Bell A; Hsu CP; Dutta S; Ahamadi M
CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):1988-2000. PubMed ID: 37723849
[TBL] [Abstract][Full Text] [Related]
9. Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results.
Gantenbein AR; Bonvin C; Kamm CP; Schankin CJ; Zecca C; Zieglgänsberger D; Merki-Feld GS; Pohl H; Rudolph N; Ryvlin P; Agosti R; Schäfer E; Meyer I; Kulartz-Schank M; Arzt ME
J Neurol; 2024 Jun; ():. PubMed ID: 38871822
[TBL] [Abstract][Full Text] [Related]
10. Comparison of indirect treatment methods in migraine prevention to address differences in mode of administration.
Fawsitt CG; Thom H; Regnier SA; Lee XY; Kymes S; Vase L
J Comp Eff Res; 2023 Jul; 12(7):e230021. PubMed ID: 37222593
[No Abstract] [Full Text] [Related]
11. Efficacy and safety of erenumab in migraine treatment.
Wang Y; Zhao H
Minerva Surg; 2024 Jun; ():. PubMed ID: 38916540
[No Abstract] [Full Text] [Related]
12. MicroRNA profiling in women with migraine: effects of CGRP-targeting treatment.
Ornello R; Zelli V; Compagnoni C; Caponnetto V; De Matteis E; Tiseo C; Tessitore A; Sacco S
J Headache Pain; 2024 May; 25(1):80. PubMed ID: 38755568
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis.
Wang X; Wen D; He Q; You C; Ma L
J Headache Pain; 2022 Sep; 23(1):105. PubMed ID: 36071388
[TBL] [Abstract][Full Text] [Related]
14. Optimal Dose of Erenumab for Preventive Treatment of Episodic Migraine: A Systematic Review and Meta-Analysis.
Yang Y; Chen M; Wu D; Sun Y; Jiang F; Chen Z; Wang Z
Curr Neuropharmacol; 2022; 20(2):460-470. PubMed ID: 34429056
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of erenumab in women with a history of menstrual migraine.
Pavlovic JM; Paemeleire K; Göbel H; Bonner J; Rapoport A; Kagan R; Zhang F; Picard H; Mikol DD
J Headache Pain; 2020 Aug; 21(1):95. PubMed ID: 32746775
[TBL] [Abstract][Full Text] [Related]
16. Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety.
Lattanzi S; Brigo F; Trinka E; Vernieri F; Corradetti T; Dobran M; Silvestrini M
Drugs; 2019 Mar; 79(4):417-431. PubMed ID: 30793254
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
Ashina M; Tepper SJ; Brandes JL; Reuter U; Boudreau GP; Weatherall M; Gantenbein AR; Doležil D; Klatt J; Wang A; Karanam AK; Cheng S; Mikol DD
Headache; 2022 May; 62(5):624-633. PubMed ID: 35593783
[TBL] [Abstract][Full Text] [Related]
18. Different dosage regimens of erenumab for the treatment of migraine: A systematic review and meta-analysis of the efficacy and safety of randomized controlled trials.
Gui T; Li H; Zhu F; Wang Q; Zhou X; Xue Q
Headache; 2022 Nov; 62(10):1281-1292. PubMed ID: 36373822
[TBL] [Abstract][Full Text] [Related]
19. The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal.
Ornello R; Tiseo C; Frattale I; Perrotta G; Marini C; Pistoia F; Sacco S
J Headache Pain; 2019 Oct; 20(1):99. PubMed ID: 31666008
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
